|
|
| Type |
Oral Presentation |
| Area |
Bioconjugation |
| Room No. |
403호 |
| Time |
THU 09:30-: |
| Code |
BIO.O-4 |
| Subject |
Current status and technological trends in the development of antibody-drug conjugates |
| Authors |
이선배
(주)알테오젠 R&D center, Korea |
| Abstract |
Antibody-drug conjugates (ADCs) elicit cancer-cell specific cytotoxicity by delivering highly potent drugs selectively to antigen-expressing tumor cells. Various parameters must be considered in designing optimal ADC construct, such as optimal drug-to-antibody ratio, conjugation method, cytotoxic payloads, and antigen specific mAb. Recent advance and technological trends in this field will be presented. |
| E-mail |
|
|
119th General Meeting of the KCS